Nontuberculous mycobacterial infections in cystic fibrosis

Clinics in Chest Medicine

Volumn 36, Issue 1, 2015, Pages 101-115

  Martiniano, Stacey L ^a   Nick, Jerry A ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Atypical mycobacteria; Cystic fibrosis; Mycobacterium abscessus; Mycobacterium avium complex; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CLOFAZIMINE; ETHAMBUTOL; IMIPENEM; LINEZOLID; RIFAMPICIN; TIGECYCLINE;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; ATYPICAL MYCOBACTERIOSIS; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BREATHING EXERCISE; BRONCHIECTASIS; COMORBIDITY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG MONITORING; DRUG RESPONSE; HIGH RISK POPULATION; HUMAN; LUNG CLEARANCE; LUNG INFECTION; LUNG RESECTION; LUNG TRANSPLANTATION; MIXED INFECTION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; OUTCOME ASSESSMENT; PATHOGEN CLEARANCE; PREVALENCE; RISK FACTOR; SPUTUM CULTURE; ATYPICAL MYCOBACTERIUM; CLASSIFICATION; COMPLICATION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS;

COINFECTION; CYSTIC FIBROSIS; HUMANS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84922339881     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2014.11.003     Document Type: Review

References (119)

1. Qvist T., Pressler T., Hoiby N., et al. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res 2014, 15:41.
2. Cystic Fibrosis Foundation Patient Registry. 2012 annual data report to the center directors. Bethesda (MD): Cystic Fibrosis Foundation; 2013.
3. Stallings V.A., Stark L.J., Robinson K.A., ClinicalPractice Guidelines on Growth and Nutrition Subcommittee, Ad Hoc Working Group, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. JAm Diet Assoc 2008, 108:832-839.
4. Flume P.A., Robinson K.A., O'Sullivan B.P., et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009, 54:522-537.
5. Mogayzel P.J., Naureckas E.T., Robinson K.A., Pulmonary Clinical Practice Guidelines Committee, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187:680-689.
6. Ratjen F., Munck A., Kho P., et al. Treatment of early pseudomonas aeruginosa infection in patients with cystic fibrosis: the elite trial. Thorax 2010, 65:286-291.
7. Ong T., Ramsey B.W. Modifying disease in cystic fibrosis: current and future therapies on the horizon. Curr Opin Pulm Med 2013, 19:645-651.
8. Smith M.J., Efthimiou J., Hodson M.E., et al. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984, 39:369-375.
9. Olivier K.N., Weber D.J., Wallace R.J., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
10. Roux A.L., Catherinot E., Ripoll F., Jean-Louis Herrmann for the OMA Group, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. JClin Microbiol 2009, 47:4124-4128.
11. Esther C.R., Esserman D.A., Gilligan P., et al. Chronic mycobacterium abscessus infection and lung function decline in cystic fibrosis. JCyst Fibros 2010, 9:117-123.
12. Qvist T., Gilljam M., Jonsson B., et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in scandinavia. JCyst Fibros 2014, 14:S1569-1993. the Scandinavian Cystic Fibrosis Study Consortium (SCFSC).
13. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ats/idsa statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
14. Hsorsburgh C.R. Epidemiology of mycobacterium avium complex. Mycobacterium avium complex infection: progress in research and treatment 1996, 1-22. Marcel Dekker, New York. J.A. Korvick, C.A. Benson (Eds.).
15. Andre E., Degraux J., Simon A., et al. Absence of non-tuberculous mycobacteria recovery in sputum of cystic fibrosis patients despite adequate decontamination: a possible role of specific antimicrobial therapy used in our centre. Clin Microbiol Infect 2010, 16:S33-S34.
16. Torrens J.K., Dawkins P., Conway S.P., et al. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998, 53:182-185.
17. Sermet-Gaudelus I., Le Bourgeois M., Pierre-Audigier C., et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003, 9:1587-1591.
18. Aitken M.L., Burke W., McDonald G., et al. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 1993, 103:1096-1099.
19. Valenza G., Tappe D., Turnwald D., et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. JCyst Fibros 2008, 7:123-127.
20. Adjemian J., Olivier K.N., Prevots D.R. Nontuberculous mycobacteria among cystic fibrosis patients in the united states: screening practices and environmental risk. Am J Respir Crit Care Med 2014, 190(5):581-586.
21. Leung J.M., Olivier K.N. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med 2013, 19:662-669.
22. Adjemian J., Olivier K.N., Seitz A.E., et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012, 185:881-886.
23. Prevots D.R., Shaw P.A., Strickland D., et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010, 182:970-976.
24. Leung J.M., Olivier K.N. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013, 34:124-134.
25. Rodman D.M., Polis J.M., Heltshe S.L., et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005, 171:621-626.
26. Hjelte L., Petrini B., Kallenius G., et al. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990, 45:397-400.
27. Kilby J.M., Gilligan P.H., Yankaskas J.R., et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992, 102:70-75.
28. Esther C.R., Henry M.M., Molina P.L., et al. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005, 40:39-44.
29. Seddon P., Fidler K., Raman S., et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, united kingdom, 2009. Emerg Infect Dis 2013, 19:1128-1130.
30. Pierre-Audigier C., Ferroni A., Sermet-Gaudelus I., et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. JClin Microbiol 2005, 43:3467-3470.
31. Levy I., Grisaru-Soen G., Lerner-Geva L., et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, israel. Emerg Infect Dis 2008, 14:378-384.
32. Catherinot E., Roux A.L., Vibet M.A., et al. Mycobacterium avium and mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. JCyst Fibros 2013, 12:74-80.
33. Fauroux B., Delaisi B., Clement A., et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997, 16:354-358.
34. Hjelt K., Hojlyng N., Howitz P., et al. The role of mycobacteria other than tuberculosis (mott) in patients with cystic fibrosis. Scand J Infect Dis 1994, 26:569-576.
35. Aitken M.L., Moss R.B., Waltz D.A., et al. Aphase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001, 12:1907-1916.
36. Keating C.L., Liu X., Dimango E.A. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest 2010, 137:1157-1163.
37. Nick J.A., Chacon C.S., Brayshaw S.J., et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010, 182:614-626.
38. Ziedalski T.M., Kao P.N., Henig N.R., et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006, 130:995-1002.
39. Kim J.S., Tanaka N., Newell J.D., et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest 2005, 128:3863-3869.
40. Jang M.A., Kim S.Y., Jeong B.H., et al. Association of CFTR gene variants with nontuberculous mycobacterial lung disease in a korean population with a low prevalence of cystic fibrosis. JHum Genet 2013, 58:298-303.
41. Burgel P., Morand P., Audureau E., et al. Azithromycin and the risk of nontuberculous mycobacteria in adults with cystic fibrosis. Pediatr Pulmonol 2011, 46:328.
42. Ager S., O'Brien C., Spencer D.A., et al. Aretrospective review of non-tuberculous mycobacteria in paediatric cystic fibrosis patients at a regional centre. JCyst Fibros 2011, 10:S36.
43. Paugam A., Baixench M.T., Demazes-Dufeu N., et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in france. Med Mycol 2010, 48(Suppl 1):S32-S36.
44. Mussaffi H., Rivlin J., Shalit I., et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005, 25:324-328.
45. Evans J.T., Ratnaraja N., Gardiner S., et al. Mycobacterium abscessus in cystic fibrosis: what does it all mean?. Clin Microbiol Infect 2011, 17:S602.
46. Chalermskulrat W., Sood N., Neuringer I.P., et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006, 61:507-513.
47. Falkinham J.O. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. JAppl Microbiol 2009, 107:356-367.
48. Giron R.M., Maiz L., Barrio I., et al. nontuberculous mycobacterial infection in patients with cystic fibrosis: a multicenter prevalence study. Arch Bronconeumol 2008, 44:679-684. [in Spanish].
49. Olivier K.N., Weber D.J., Lee J.H., et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003, 167:835-840.
50. Renna M., Schaffner C., Brown K., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. JClin Invest 2011, 121:3554-3563.
51. Binder A.M., Adjemian J., Olivier K.N., et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013, 188:807-812.
52. Catherinot E., Roux A.L., Vibet M.A., OMA Group, et al. Inhaled therapies, azithromycin and mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013, 41:1101-1106.
53. Radhakrishnan D.K., Yau Y., Corey M., et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009, 44:1100-1106.
54. Bowker J.L., Thomas M.F., O'Brien C.J. Antibiotic usage as a risk factor for non-tuberculous mycobacterium infection in children with cystic fibrosis. Thorax 2013, 68:A111-A112.
55. MacNeil S.J., Vamvakas G., Rosenthal M. NTM: lessons from the UK CF registry. JCyst Fibros 2014, 13:S71.
56. Harris K.A., Kenna D.T., Blauwendraat C., et al. Molecular fingerprinting of mycobacterium abscessus strains in a cohort of pediatric cystic fibrosis patients. JClin Microbiol 2012, 50:1758-1761.
57. Bryant J.M., Grogono D.M., Greaves D., et al. Whole-genome sequencing to identify transmission of mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013, 381:1551-1560.
58. Aitken M.L., Limaye A., Pottinger P., et al. Respiratory outbreak of mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012, 185:231-232.
59. Jonsson B.E., Gilljam M., Lindblad A., et al. Molecular epidemiology of mycobacterium abscessus, with focus on cystic fibrosis. JClin Microbiol 2007, 45:1497-1504.
60. Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. JPediatr 1980, 96:689-691.
61. Whittier S., Olivier K., Gilligan P., et al. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. The nontuberculous mycobacteria in cystic fibrosis study group. JClin Microbiol 1997, 35:2706-2708.
62. Bange F.C., Bottger E.C. Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2002, 21:546-548.
63. Whittier S., Hopfer R.L., Knowles M.R., et al. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. JClin Microbiol 1993, 31:861-864.
64. Oliver A., Maiz L., Canton R., et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001, 32:1298-1303.
65. Steingart K.R., Ng V., Henry M., et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006, 6:664-674.
66. Brown-Elliott B.A., Griffith D.E., Wallace R.J. Diagnosis of nontuberculous mycobacterial infections. Clin Lab Med 2002, 22:911-925. vi.
67. Buijtels P.C., Petit P.L. Comparison of naoh-n-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens. JMicrobiol Methods 2005, 62:83-88.
68. Bange F.C., Kirschner P., Bottger E.C. Recovery of mycobacteria from patients with cystic fibrosis. JClin Microbiol 1999, 37:3761-3763.
69. Ferroni A., Vu-Thien H., Lanotte P., et al. Value of the chlorhexidine decontamination method for recovery of nontuberculous mycobacteria from sputum samples of patients with cystic fibrosis. JClin Microbiol 2006, 44:2237-2239.
70. Martiniano S.L., Sontag M.K., Daley C.L., et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014, 11:36-44.
71. Ebert D.L., Olivier K.N. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002, 23:655-663.
72. Doucet-Populaire F., Buriankova K., Weiser J., et al. Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2002, 2:355-370.
73. Verma N., Spencer D. Disseminated mycobacterium gordonae infection in a child with cystic fibrosis. Pediatr Pulmonol 2012, 47:517-518.
74. Segal E., Diez G.S., Prokopio E., et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Medicina 1998, 58:257-261. [in Spanish].
75. Mulherin D., Coffey M.J., Halloran D.O., et al. Skin reactivity to atypical mycobacteria in cystic fibrosis. Respir Med 1990, 84:273-276.
76. Ngan G.J., Ng L.M., Jureen R., et al. Development of multiplex pcr assays based on the 16s-23s rrna internal transcribed spacer for the detection of clinically relevant nontuberculous mycobacteria. Lett Appl Microbiol 2011, 52:546-554.
77. Leung K.L., Yip C.W., Cheung W.F., et al. Development of a simple and low-cost real-time pcr method for the identification of commonly encountered mycobacteria in a high throughput laboratory. JAppl Microbiol 2009, 107:1433-1439.
78. Devine M., Moore J.E., Xu J., et al. Detection of mycobacterial DNA from sputum of patients with cystic fibrosis. Ir J Med Sci 2004, 173:96-98.
79. Ferroni A., Sermet-Gaudelus I., Le Bourgeois M., et al. Measurement of immunoglobulin g against mycobacterial antigen a60 in patients with cystic fibrosis and lung infection due to mycobacterium abscessus. Clin Infect Dis 2005, 40:58-66.
80. Cullen A.R., Cannon C.L., Mark E.J., et al. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection?. Am J Respir Crit Care Med 2000, 161:641-645.
81. Catherinot E., Roux A.L., Macheras E., et al. Acute respiratory failure involving an r variant of mycobacterium abscessus. JClin Microbiol 2009, 47:271-274.
82. Forslow U., Geborek A., Hjelte L., et al. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis. Acta Paediatr 2003, 92:910-915.
83. Leitritz L., Griese M., Roggenkamp A., et al. Prospective study on nontuberculous mycobacteria in patients with and without cystic fibrosis. Med Microbiol Immunol 2004, 193:209-217.
84. Waters V., Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2012, (12). CD010004.
85. van Ingen J., Egelund E.F., Levin A., et al. The pharmacokinetics and pharmacodynamics of pulmonary mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012, 186(6):559-565.
86. Clement A., Tamalet A., Leroux E., et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61:895-902.
87. Equi A., Balfour-Lynn I.M., Bush A., et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
88. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
89. Wolter J., Seeney S., Bell S., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
90. Gilljam M., Berning S.E., Peloquin C.A., et al. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999, 14:347-351.
91. Anselmo M.A., Lands L.C. Cystic fibrosis: overview. Pediatric respiratory medicine 2008, 845-857. Mosby Inc, Philadelphia. 2nd edition. L.M. Taussig, L.I. Landau (Eds.).
92. Donaldson S.H., Bennett W.D., Zeman K.L., et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. NEngl J Med 2006, 354:241-250.
93. Elkins M.R., Robinson M., Rose B.R., et al. Acontrolled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. NEngl J Med 2006, 354:229-240.
94. Aitken M.L., Bellon G., De Boeck K., et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012, 185:645-652.
95. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human dnase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. NEngl J Med 1994, 331:637-642.
96. Bange F.C., Brown B.A., Smaczny C., et al. Lack of transmission of mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 2001, 32:1648-1650.
97. Saiman L., Siegel J.D., LiPuma J.J., et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014, 35:S1-S67.
98. Jarand J., Levin A., Zhang L., et al. Clinical and microbiologic outcomes in patients receiving treatment for mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011, 52:565-571.
99. Kearns G.L., Trang J.M. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. JPediatr 1986, 108:847-853.
100. de Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet 1987, 13:228-253.
101. Rey E., Treluyer J.M., Pons G. Drug disposition incystic fibrosis. Clin Pharmacokinet 1998, 35:313-329.
102. Wallace R.J., Brown B.A., Griffith D.E., et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for mycobacterium avium-m. Intracellulare infection. JInfect Dis 1995, 171:747-750.
103. Peloquin C.A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62:2169-2183.
104. Moriarty T.F., McElnay J.C., Elborn J.S., et al. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007, 42:1008-1017.
105. Huang Y.C., Liu M.F., Shen G.H., et al. Clinical outcome of mycobacterium abscessus infection and antimicrobial susceptibility testing. JMicrobiol Immunol Infect 2010, 43:401-406.
106. Braun A.T., Merlo C.A. Cystic fibrosis lung transplantation. Curr Opin Pulm Med 2011, 17:467-472.
107. Orens J.B., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. JHeart Lung Transpl 2006, 25:745-755.
108. Taylor J.L., Palmer S.M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. JHeart Lung Transpl 2006, 25:985-988.
109. Zaidi S., Elidemir O., Heinle J.S., et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009, 11:243-248.
110. Sanguinetti M., Ardito F., Fiscarelli E., et al. Fatal pulmonary infection due to multidrug-resistant mycobacterium abscessus in a patient with cystic fibrosis. JClin Microbiol 2001, 39:816-819.
111. Flume P.A., Egan T.M., Paradowski L.J., et al. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994, 149:1601-1607.
112. Gilljam M., Schersten H., Silverborn M., et al. Lung transplantation in patients with cystic fibrosis and mycobacterium abscessus infection. JCyst Fibros 2010, 9:272-276.
113. Watkins R.R., Lemonovich T.L. Evaluation of infections in the lung transplant patient. Curr Opin Infect Dis 2012, 25:193-198.
114. Accurso F.J., Rowe S.M., Clancy J.P., et al. Effect of vx-770 in persons with cystic fibrosis and the g551d-cftr mutation. NEngl J Med 2010, 363:1991-2003.
115. Falkinham J.O. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011, 17:419-424.
116. Thomson R., Tolson C., Carter R., et al. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. JClin Microbiol 2013, 51:3006-3011.
117. Feazel L.M., Baumgartner L.K., Peterson K.L., et al. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci U S A 2009, 106:16393-16399.
118. Ballarino G.J., Olivier K.N., Claypool R.J., et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009, 103:1448-1455.
119. Rowe S.M., Borowitz D.S., Burns J.L., et al. Progress in cystic fibrosis and the cf therapeutics development network. Thorax 2012, 67:882-890.